$-0.37
(Market cap
$5,455 Mln
Revenue (TTM)
$1,139 Mln
P/E Ratio
--
P/B Ratio
5.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-15.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.4
-
Face value
--
-
Shares outstanding
185,739,792
7 Years Aggregate
CFO
$-783.72 Mln
EBITDA
$-1,674.51 Mln
Net Profit
$-1,780.68 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Legend Biotech Corp (LEGN)
| 34.1 | 22.0 | 51.2 | 0.9 | -22.7 | -4.9 | -- |
|
BSE Sensex
| -10.4 | -1.0 | -7.8 | -7.7 | 6.7 | 8.3 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Legend Biotech Corp (LEGN)
| -33.2 | -45.6 | 20.5 | 7.1 | 65.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Legend Biotech Corp (LEGN)
|
29.2 | 5,455.2 | 1,138.9 | -250.2 | -19.3 | -25.3 | -- | 5.6 |
| 79.0 | 10,557.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 17.3 | |
| 77.5 | 10,446.2 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 50.5 | 12,605.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.6 | 6.4 | |
| 124.6 | 15,772.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 69.9 | 8,103.6 | 1,508.5 | 348.8 | 57.0 | 96.4 | 24 | 36.9 | |
| 305.5 | 8,827.7 | 417.3 | 225.0 | 42.8 | 18.6 | 40 | 6.9 | |
| 526.7 | 11,925.8 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.0 | |
| 430.7 | 12,360.6 | 2,678.3 | 460.4 | 21.1 | 103.2 | 27.3 | 20.7 | |
| 355.5 | 9,578.0 | 0.0 | -326.5 | -- | -37.2 | -- | 6.8 |
Shareholding Pattern
View DetailsAbout Legend Biotech Corp (LEGN)
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.... Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey. Address: 2101 Cottontail Lane, Somerset, NJ, United States, 08873 Read more
-
CEO & Director
Dr. Ying Huang Ph.D.
-
CEO & Director
Dr. Ying Huang Ph.D.
-
Headquarters
Somerset, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Legend Biotech Corp (LEGN)
What is the current share price of Legend Biotech Corp (LEGN) Today?
The share price of Legend Biotech Corp (LEGN) is $29.16 (NASDAQ) as of 27-May-2026 12:39 EDT. Legend Biotech Corp (LEGN) has given a return of -22.7% in the last 3 years.
What is the current PB & PE ratio of Legend Biotech Corp (LEGN)?
Since, TTM earnings of Legend Biotech Corp (LEGN) is negative, P/E ratio is not available.
The P/B ratio of Legend Biotech Corp (LEGN) is 5.64 times as on 22-May-2026, a 33 premium to its peers’ median range of 4.24 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-13.48
|
3.99
|
|
2024
|
-33.64
|
5.72
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
-16.28
|
8.58
|
What is the 52 Week High and Low of Legend Biotech Corp (LEGN)?
The 52-week high and low of Legend Biotech Corp (LEGN) are Rs 45.30 and Rs 16.24 as of 27-May-2026.
What is the market cap of Legend Biotech Corp (LEGN)?
Legend Biotech Corp (LEGN) has a market capitalisation of $ 5,455 Mln as on 22-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Legend Biotech Corp (LEGN)?
Before investing in Legend Biotech Corp (LEGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.